The “Cancer Cachexia – Pipeline Insight, 2020” drug pipelines have been added to ResearchAndMarkets.com’s offering.
The “Cancer Cachexia – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Cancer Cachexia pipeline landscape.
It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cancer Cachexia Emerging Drugs Chapters
This segment of the Cancer Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cancer Cachexia Emerging Drugs
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Macimorelin: Aeterna Zentaris
Macimorelin stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. Zentaris is conducting a pilot clinical trial of repeated doses of macimorelin to assess safety and efficacy in patients with cancer cachexia. The purpose of this study is to evaluate the safety and efficacy of repeated oral administration of macimorelin at different doses daily for 1 week for the treatment of cancer cachexia.
PF- 06946860: Pfizer
Pfizer is conducting a phase 1, randomized, double-blind, sponsor-open, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of single-dose, subcutaneous administration of PF 06946860 to healthy adult subjects. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06946860 in healthy adult subjects following single ascending doses This is the first clinical study of PF-06946860.
Cancer Cachexia: Therapeutic Assessment
This segment of the report provides insights about the different Cancer Cachexia drugs segregated based on the following parameters that define the scope of the report, such:
Major Players in Cancer Cachexia
There are approx. 10+ key companies are developing therapies for Cancer Cachexia. The companies which have their Cancer Cachexia drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Tetra Bio-Pharma, Helsinn Healthcare, etc.
Source: Businesswire
